Importantly, multiple agent therapy of a low dose of each of sildenafil and PT-141 appeared to result in a thereapeutic benefit equivalent to a pharmacologically active higher dose of either agent as monotherapy, without the attendant adverse events associated with higher dose monotherapy
Until then, PAs for weight-loss indications are ending and expire Dec 31, 2025
Intranasal DSIP is used by some practitioners and avoids needles
Fatigue, loss of appetite beyond the intended therapeutic effect, and dizziness appear in roughly 1020% of users
A drug might have a compound patent expiring in Year 10, an NCE exclusivity running to Year 5, formulation patents running to Year 14, and pediatric exclusivity adding six months to everything producing an effective exclusivity window that extends to Year 14.5, despite a nominal compound patent expiry in Year 10
Understanding what sets them apart can help you have clear conversations with your healthcare provider about which is the right choice for you